-
1 month ago | 
onclive.com | Darlene Dobkowski
Enfortumab vedotin (Padcev) demonstrated a manageable safety profile and no unexpected toxicities in patients aged 80 years and older with urothelial carcinoma, according to findings from a real-word study presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium. More patients aged 85 years and older received upfront Padcev dose reduction. There were fewer grade 2/3 (moderate to severe) treatment-related side effects with lower starting doses of Padcev.
-
1 month ago | 
curetoday.com | Darlene Dobkowski |Alex Biese
As an expert explained in an interview with CURE, we may be in the midst of a “new era” for small cell lung cancer research. This optimism comes in the wake of the Food and Drug Administration’s (FDA’s) approval of Imdelltra (tarlatamab-dlle) in May 2024 for the treatment of patients with extensive-stage small cell lung cancer (SCLC).
-
1 month ago | 
curetoday.com | Alex Biese |Darlene Dobkowski
Ensacove (ensartinib) has been approved by the Food and Drug Administration (FDA) for adults with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor. Ensacove’s efficacy was displayed in the phase 3 eXALT3 clinical trial of 290 patients with locally advanced or metastatic ALK-positive NSCLC who were naïve to prior ALK-targeted therapy.
-
1 month ago | 
curetoday.com | Alex Biese |Darlene Dobkowski
The Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) for adults with limited-stage small cell lung cancer (SCLC) whose disease did not progress after concurrent platinum-based chemotherapy and radiation therapy. The late 2024 approval was based on findings form the ADRIATIC trial of 730 patients with limited-stage SCLC.
-
1 month ago | 
curetoday.com | Alex Biese |Darlene Dobkowski
The Food and Drug Administration (FDA) has granted its first approval for a systemic therapy for patients with non-small cell lung cancer (NSCLC) with an Neuregulin 1 (NRG1) gene fusion, with the accelerated approval of Bizengri (zenocutuzumab-zbco). The FDA approved Bizengri in late 2024 for the treatment of advanced, unresectable or metastatic NSCLC with a NRG1 gene fusion with disease progression on or after prior systemic therapy.
-
1 month ago | 
onclive.com | Darlene Dobkowski
Findings from a retrospective study showed that patients with advanced urothelial carcinoma who were at least 80 years of age did not experience excessive or unexpected toxicity when treated with enfortumab vedotin-ejfv (Padcev) with or without pembrolizumab.1Results from this study, which were presented at the 2025 Genitourinary Cancers Symposium, also demonstrated that more patients aged 85 years and older received upfront enfortumab vedotin dose reduction.
-
2 months ago | 
onclive.com | Darlene Dobkowski
Clinical practice gaps in the management of metastatic castration-resistant prostate cancer (mCRPC) include a lack of germline or somatic testing, delayed homologous recombination repair (HRR) testing, and delayed PARP inhibitor therapy, according to data from an extended real-world analysis that were presented at the 2025 Genitourinary Cancers Symposium.1 In total, 81% of patients included in the analysis (n = 1022) did not receive HRR testing at the time of diagnosis, and 35% of patients...
-
2 months ago | 
targetedonc.com | Darlene Dobkowski
Olanzapine may help manage adverse events (AEs) such as vomiting, nausea, insomnia, anorexia, and weight loss from tyrosine kinase inhibitors (TKIs), though further randomized, placebo-controlled studies are needed to confirm these findings.1Findings from this retrospective study were presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium.
-
2 months ago | 
oncnursingnews.com | Darlene Dobkowski
Olanzapine may be effective in managing adverse effects (AEs) from tyrosine-kinase inhibitors (TKIs) including vomiting, nausea, insomnia, anorexia, and weight loss, although prospective, randomized, placebo-controlled studies are needed to confirm these results. Findings from this retrospective study were presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium.
-
2 months ago | 
curetoday.com | Darlene Dobkowski
Treatment with Padcev (enfortumab vedotin) for urothelial carcinoma, a type of bladder cancer, may not cause excessive or unexpected side effects particularly in patients aged 80 years and older, recent study findings suggest. Of note, results from this study, which were presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, were from a small patient population and based on an assessment of patients after they were treated.
